Enhanced High Penetration Prodrug Compositions for Pulmonary Conditions

Publication ID: 24-11857545_0006_PTD
Published: October 28, 2025
Category:Direct Improvements & Enhancements

Legal Citation

pr1or.art Inc., “Enhanced High Penetration Prodrug Compositions for Pulmonary Conditions,” Published Technical Disclosure No. 24-11857545_0006_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857545_0006_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,545.

Summary of the Inventive Concept

This inventive concept relates to improved high penetration prodrug compositions and pharmaceutical formulations for treating pulmonary conditions, enhancing penetration across biological barriers and reducing side effects.

Background and Problem Solved

The original patent disclosed high penetration prodrug compositions for treating pulmonary conditions, but had limitations in terms of solubility, delivery, and side effects. The new inventive concept addresses these limitations by introducing novel formulations, carriers, and delivery systems that enhance penetration, solubility, and targeting, while reducing side effects.

Detailed Description of the Inventive Concept

The new inventive concept comprises four main aspects: (1) a method of treating pulmonary conditions using high penetration prodrug compositions, (2) a pharmaceutical composition with improved solubility and delivery, (3) a system for delivering the composition with real-time monitoring and dosage adjustment, and (4) a novel manufacturing process. The high penetration prodrug composition is formulated to enhance penetration across biological barriers and reduce side effects associated with the pulmonary condition. The carrier is designed to improve solubility and enhance delivery to the site of action. The system for delivering the composition includes a device for administering the composition and a sensor for monitoring the patient's response to the treatment, with the ability to adjust the dosage based on the patient's response. The manufacturing process involves synthesizing a functional unit, linking it to a transportational unit, and formulating the resulting high penetration prodrug composition into a pharmaceutical dosage form.

Novelty and Inventive Step

The new inventive concept introduces novel formulations, carriers, and delivery systems that enhance penetration, solubility, and targeting, while reducing side effects. The system for delivering the composition with real-time monitoring and dosage adjustment is a significant improvement over the original patent. The manufacturing process is also novel and non-obvious, providing a more efficient and effective way of producing the high penetration prodrug composition.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept include using different types of carriers, varying the ratio of functional units to transportational units, and incorporating additional components to enhance targeting and delivery. Variations of the system for delivering the composition could include using different types of sensors or devices for administering the composition.

Potential Commercial Applications and Market

The enhanced high penetration prodrug compositions and pharmaceutical formulations have significant commercial potential in the treatment of pulmonary conditions, including asthma, lower and upper respiratory tract infections. The target market includes pharmaceutical companies, hospitals, and clinics, with potential revenue streams from licensing, manufacturing, and sales.

Field of Art

Pharmaceutical formulations, specifically prodrug compositions for pulmonary condition treatment, requiring advanced knowledge of organic chemistry, pharmaceutical sciences, drug delivery systems, and biological barrier penetration technologies

Person of Ordinary Skill (PHOSITA) Profile

A pharmaceutical scientist with a PhD or equivalent industrial experience in drug formulation, expertise in medicinal chemistry, understanding of prodrug design, biological barrier penetration mechanisms, and pharmaceutical delivery systems

Obviousness Rationale

A PHOSITA would recognize that the PTD's variations represent predictable extensions of the source patent's core prodrug composition technology. The disclosed improvements in delivery systems, carrier design, and manufacturing processes are logical incremental advancements that would be obvious to a skilled practitioner seeking to optimize pulmonary drug delivery. The PTD's claims represent routine optimization of known pharmaceutical design principles applied to the existing prodrug composition framework.

Obvious Combinations & Variations

Source Patent Element
Topical pharmaceutical formulation for pulmonary conditions with specific structural compounds
PTD Variation
Enhanced high penetration prodrug composition with improved carrier and delivery system
Obviousness Reasoning
Known pharmaceutical design principle of improving drug delivery through carrier modifications and targeted transport mechanisms, representing a predictable solution to enhance drug efficacy
Source Patent Element
Spray-based topical application method
PTD Variation
Real-time monitoring system with dosage adjustment capabilities
Obviousness Reasoning
Logical extension of existing delivery methods, utilizing standard sensor and feedback technologies to create a more responsive drug administration approach
Source Patent Element
Specific prodrug structural configurations
PTD Variation
Functional unit and transportational unit design for enhanced receptor targeting
Obviousness Reasoning
Routine pharmaceutical engineering approach of modifying molecular design to improve drug specificity and reduce side effects, using known chemical linkage and targeting strategies
Source Patent Element
Pharmaceutical composition for pulmonary conditions
PTD Variation
Manufacturing process involving functional and transportational unit synthesis
Obviousness Reasoning
Standard chemical synthesis techniques applied to prodrug development, representing an obvious method of improving production efficiency through systematic molecular design
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857545, the present published technical disclosure demonstrates that the claimed variations in high penetration prodrug compositions, delivery systems, and manufacturing processes would have been obvious to a person having ordinary skill in pharmaceutical formulation at the time of invention. The disclosed improvements represent predictable extensions of existing prodrug technology, utilizing known techniques of carrier modification, molecular design, and delivery system optimization.

Original Patent Information

Patent NumberUS 11,857,545
TitleHigh penetration prodrug compositions and pharmaceutical composition thereof for treatment of pulmonary conditions
Assignee(s)Techfields Pharma Co., Ltd.